Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System

In July, the US FDA approved AstraZeneca’s (AZ) lung cancer drug Iressa (gefitinib) for the first-line treatment of EGFR mutation-positive, advanced or metastatic non-small cell lung cancer (NSCLC). Thirteen years have passed since Iressa won the world’s first approval in...read more